Research directory

Clinical trials

Find trials by company, ticker, title or NCT ID.

Filters
Reset
1,647 trials match your filters.
TrialSponsorPhaseStatusPrimary completion
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksNCT02303626BioCryst PharmaceuticalsPhase 2, Phase 3Completed2016-01Actual
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeNCT02311673RYTMPhase 2Completed2016-10-26Actual
Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh SyndromeNCT02352896PTC TherapeuticsPhase 2Completed2023-10-30Actual
An Extension of Protocol PRO 140_CD01 StudyNCT02355184CytoDyn, Inc.Phase 2Terminated2022-06Actual
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic MelanomaNCT02360579IOVAPhase 2Completed2024-10-24Actual
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsNCT02383927KURAPhase 2Completed2020-12-14Actual
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related ConditionsNCT02421679Tonix Pharmaceuticals, Inc.Phase 2Completed2016-05-26Actual
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaNCT02436096Tonix Pharmaceuticals, Inc.Phase 3Completed2016-09Actual
CardiAMP™ Cell Therapy for Heart Failure TrialNCT02438306BCDAPhase 3Completed2025-02Actual
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaNCT02446093CADLPhase 2Unknown2025-12Estimated
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusNCT02452528Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyNCT02464228KURAPhase 2Completed2021-03-31Actual
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)NCT02465957IBRXPhase 2Terminated2018-03-19Actual
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatNCT02474589SIGA TechnologiesPhase 3Completed2016-08-24Actual
A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyNCT02476916AGIOPhase 2Completed2017-05-08Actual
A Study With SAGE-547 for Super-Refractory Status EpilepticusNCT02477618SUPNPhase 3Completed2017-07-18Actual
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711MacroGenicsPhase 3Completed2021-08-11Actual
Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenNCT02500316OPKPhase 2Completed2023-11Actual
Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)NCT02501018LSTAPhase 2Completed2022-05-19Actual
Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisNCT02503657MediciNovaPhase 2Completed2020-12-07Actual
Oral ONC201 in Adult Recurrent GlioblastomaNCT02525692Jazz PharmaceuticalsPhase 2Terminated2023-04-17Actual
A Pre-Surgical PK Study of IM and Intraductally Delivered FulvestrantNCT02540330ATOSPhase 2Terminated2020-08-13Actual
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)NCT02577029Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual
Acute Hip Fracture Study in Patients 65 Years or GreaterNCT02578095VKTXPhase 2Completed2017-11-15Actual
A Safety and Activity Study of NS2 in Subjects With Allergic ConjunctivitisNCT02578914ALDXPhase 2Completed2015-12Actual
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia PatientsNCT02589275Tonix Pharmaceuticals, Inc.Phase 3Completed2016-09-28Actual
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)NCT02591862AKARI TherapeuticsPhase 2Completed2018-03-20Actual
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)NCT02598661Geron CorporationPhase 2, Phase 3Active not recruiting2023-10-13Actual
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) InfectionNCT02604199Arrowhead PharmaceuticalsPhase 2Terminated2017-01Actual
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionNCT02604212Arrowhead PharmaceuticalsPhase 2Terminated2016-12Actual

Primary completion marks the end of data collection for the main study measures, not a results publication date.